Bayer, Arvinas partner to develop proteolysis-targeting chimera candidates for humans and plants
- by Team ABLE - 06 Jun, 2019
Bayer has announced a collaboration with Arvinas, Inc., a biopharmaceutical company based in New Haven, Connecticut. The new life science research partnership uniquely leverages the full potential of Arvinas’ novel PROTACtechnology, coupled with Bayer’s expertise in health and agriculture to develop innovations for the benefit of patients and farmers.
Arvinas’ PROTAC technology harnesses the naturally occurring protein degradation system of the cell to selectively remove target proteins by proteolysis, the breakdown of proteins into amino acids.For Bayerthe collaboration demonstrates the utilization of potential synergies of emerging and converging research across human and plant applications that is unprecedented in the life science sector.
Bayer will form an exclusive joint venture as the first company to explore the PROTAC technology in agriculture for crop protection, and at the same time establish a target-based pharmaceutical research collaboration with Arvinas. In addition, Bayer will make an equity investment to sustain its commitment for the technology
Under the terms of the agreement, Arvinas will receive an upfront payment and pharmaceutical R&D support over the next four years, as well as a direct equity investment. These investments combined will exceed USD 60 million. Bayer will own the rights to novel lead structures generated in the course of the collaboration. As programs progress through research, development, and commercialization, Arvinas might also be eligible to receive pre-defined development milestones of over USD 685 million and commercial royalties.
“As the first company founded to explore targeted protein degradation, we’ve been excited about the potential to improve the lives of patients since our inception,” said John Houston, Ph.D., President and CEO of Arvinas. “We’ve also anticipated the broad potential of our PROTAC® platform to move beyond treating human disease. This collaboration enables us not only to expand our platform into new therapeutic areas, but also begins a new journey in applying our approach to agriculture.”
The agreement, worth more than USD 110 million, includes the first-ever research application of proteolysis-targeting Chimera.